Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors

被引：54

作者：

Abdou, Yara ^{[1
]}

Goudarzi, Atta ^{[2
]}

Yu, Jia Xin ^{[3
]}

Upadhaya, Samik ^{[4
]}

Vincent, Benjamin ^{[1
]}

Carey, Lisa A. ^{[1
]}

机构：

[1] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA

[2] Univ Buffalo, Dept Med, Buffalo, NY 14203 USA

[3] Parker Inst Canc Immunotherapy, San Francisco, CA 94129 USA

[4] Canc Res Inst, New York, NY 10006 USA

来源：

NPJ BREAST CANCER | 2022年 / 8卷 / 01期

关键词：

TUMOR-INFILTRATING LYMPHOCYTES; RANDOMIZED PHASE-II; METASTATIC BREAST; NEOADJUVANT CHEMOTHERAPY; TALIMOGENE LAHERPAREPVEC; T-CELLS; PEPTIDE VACCINE; DENDRITIC CELLS; DOUBLE-BLIND; TRIAL;

D O I：

10.1038/s41523-022-00486-y

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The development of immunotherapy agents has revolutionized the field of oncology. The only FDA-approved immunotherapeutic approach in breast cancer consists of immune checkpoint inhibitors, yet several novel immune-modulatory strategies are being actively studied and appear promising. Innovative immunotherapeutic strategies are urgently needed in triple negative breast cancer (NBC), a subtype of breast cancer known for its poor prognosis and its resistance to conventional treatments. TNBC is more primed to respond to immunotherapy given the presence of more tumor infiltrating lymphocytes, higher PD-L1 expression, and higher tumor mutation burden relative to the other breast cancer subtypes, and therefore, immuno-oncology represents a key area of promise for TNBC research. The aim of this review is to highlight current data and ongoing efforts to establish the safety and efficacy of immunotherapeutic approaches beyond checkpoint inhibitors in TNBC.

引用

页数：10

共 116 条

[1] Current Landscape of Immunotherapy in Breast Cancer: A Review
Adams, Sylvia
Gatti-Mays, Margaret E.
Kalinsky, Kevin
Korde, Larissa A.
Sharon, Elad
Amiri-Kordestani, Laleh
Bear, Harry
McArthur, Heather L.
Frank, Elizabeth
Perlmutter, Jane
Page, David B.
Vincent, Benjamin
Hayes, Jennifer F.
Gulley, James L.
Litton, Jennifer K.
Hortobagyi, Gabriel N.
Chia, Stephen
Krop, Ian
White, Julia
Sparano, Joseph
Disis, Mary L.
Mittendorf, Elizabeth A.
[J]. JAMA ONCOLOGY, 2019, 5 (08) : 1205 - 1214
[2] NY-ESO-1 Cancer Testis Antigen Demonstrates High Immunogenicity in Triple Negative Breast Cancer
Ademuyiwa, Foluso O.
Bshara, Wiam
Attwood, Kristopher
Morrison, Carl
Edge, Stephen B.
Ambrosone, Christine B.
O'Connor, Tracey L.
Levine, Ellis G.
Miliotto, Anthony
Ritter, Erika
Ritter, Gerd
Gnjatic, Sacha
Odunsi, Kunle
[J]. PLOS ONE, 2012, 7 (06):
[3] A phase I clinical trial of malignant pleural disease treated with regionally delivered autologous mesothelin-targeted CAR T cells: Safety and efficacy
Adusumilli, Prasad S.
Zauderer, Marjorie G.
Rusch, Valerie W.
O'Cearbhaill, Roisin E.
Zhu, Amy
Ngai, Daniel A.
McGee, Erin
Chintala, Navin K.
Messinger, John C.
Vincent, Alain
Halton, Elizabeth F.
Diamonte, Claudia
Pineda, John
Modi, Shanu
Solomon, Stephen B.
Jones, David R.
Brentjens, Renier J.
Riviere, Isabelle
Sadelain, Michel
[J]. CANCER RESEARCH, 2019, 79 (13)
[4] MHC-II neoantigens shape tumour immunity and response to immunotherapy
Alspach, Elise
Lussier, Danielle M.
Miceli, Alexander P.
Kizhvatov, Ilya
DuPage, Michel
Luoma, Adrienne M.
Meng, Wei
Lichti, Cheryl F.
Esaulova, Ekaterina
Vomund, Anthony N.
Runci, Daniele
Ward, Jeffrey P.
Gubin, Matthew M.
Medrano, Ruan F. V.
Arthur, Cora D.
White, J. Michael
Sheehan, Kathleen C. F.
Chen, Alex
Wucherpfennig, Kai W.
Jacks, Tyler
Unanue, Emil R.
Artyomov, Maxim N.
Schreiber, Robert D.
[J]. NATURE, 2019, 574 (7780) : 696 - +
[5] Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses
Avigan, D
Vasir, B
Gong, JL
Borges, V
Wu, ZK
Uhl, L
Atkins, M
Mier, J
McDermott, D
Smith, T
Giallambardo, N
Stone, C
Schadt, K
Dolgoff, J
Tetreault, JC
Villarroel, M
Kufe, D
[J]. CLINICAL CANCER RESEARCH, 2004, 10 (14) : 4699 - 4708
[6] Expression of MAGE-A3/6 in Primary Breast Cancer is Associated With Hormone Receptor Negative Status, High Histologic Grade, and Poor Survival
Ayyoub, Maha
Scarlata, Clara-Maria
Hamai, Ahmed
Pignon, Pascale
Valmori, Danila
[J]. JOURNAL OF IMMUNOTHERAPY, 2014, 37 (02) : 73 - 76
[7] First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients
Berinstein, Neil L.
Karkada, Mohan
Morse, Michael A.
Nemunaitis, John J.
Chatta, Gurkamal
Kaufman, Howard
Odunsi, Kunle
Nigam, Rita
Sammatur, Leeladhar
MacDonald, Lisa D.
Weir, Genevieve M.
Stanford, Marianne M.
Mansour, Marc
[J]. JOURNAL OF TRANSLATIONAL MEDICINE, 2012, 10
[8] Effect of a novel IL-2 cytokine immune agonist (NKTR-214) on proliferating CD8+T cells and PD-1 expression on immune cells in the tumor microenvironment in patients with prior checkpoint therapy.
Bernatchez, Chantale
Haymaker, Cara L.
Hurwitz, Michael E.
Kluger, Harriet M.
Tetzlaff, Michael T.
Jackson, Natalie
Gergel, Ivan
Tagliaferri, Mary Ann
Zalevsky, Jonathan
Hoch, Ute
Fanton, Christie
Iacucci, Ernesto
Aung, Sandra
Imperiale, Michael
Liao, Ej
Bentebibel, Salah E.
Tannir, Nizar M.
Hwu, Patrick
Sznol, Mario
Diab, Adi
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[9] A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213.
Bernstein, V.
Ellard, S. L.
Dent, S. F.
Tu, D.
Mates, M.
Dhesy-Thind, S. K.
Panasci, L.
Gelmon, K. A.
Salim, M.
Song, X.
Clemons, M.
Ksienski, D.
Verma, S.
Simmons, C.
Lui, H.
Chi, K.
Feilotter, H.
Hagerman, L. J.
Seymour, L.
[J]. BREAST CANCER RESEARCH AND TREATMENT, 2018, 167 (02) : 485 - 493
[10] Cytokines in clinical cancer immunotherapy
Berraondo, Pedro
Sanmamed, Miguel F.
Ochoa, Maria C.
Etxeberria, Inaki
Aznar, Maria A.
Luis Perez-Gracia, Jose
Rodriguez-Ruiz, Maria E.
Ponz-Sarvise, Mariano
Castanon, Eduardo
Melero, Ignacio
[J]. BRITISH JOURNAL OF CANCER, 2019, 120 (01) : 6 - 15

← 1 2 3 4 5 6 7 8 9 10 →